Ran Nussbaum - Jun 6, 2022 Form 4/A - Amendment Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jun 6, 2022
Transactions value $
$5,150
Form type
4/A - Amendment
Date filed
2/28/2023, 11:29 AM
Date Of Original Report
Aug 25, 2022
Previous filing
Jun 3, 2022
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise $5.15K +1.03K +0.07% $5.00* 1.43M Jun 6, 2022 Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Options Exercise $0 -1.03K -100% $0.00* 0 Jun 6, 2022 Ordinary Shares 1.03K $5.00 By Pontifax Cayman III Limited Partnership F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares.
F2 On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022.